Publicacions en col·laboració amb investigadors/es de Instituto de Investigación Biomédica de Salamanca (15)

2022

  1. Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells

    Therapeutic Advances in Hematology, Vol. 13

2021

  1. Magnetic resonance myocardial feature tracking in transfusion-dependent myelodysplastic syndrome

    Journal of Cardiovascular Imaging, Vol. 29, Núm. 4, pp. 331-344

2019

  1. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

    Blood

  2. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

  3. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity

    British Journal of Haematology, Vol. 187, Núm. 1, pp. 93-104

2018

  1. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

    British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359

  2. Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes [Oncotarget, 8 (2017) (106948-106961)] DOI: 10.18632/oncotarget.22157

    Oncotarget

2017

  1. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts

    Leukemia Research, Vol. 56, pp. 82-87

  2. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group

    American Journal of Hematology, Vol. 92, Núm. 9, pp. E534-E541

  3. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

    Oncotarget, Vol. 8, Núm. 63, pp. 106948-106961

2016

  1. Bone marrow fibrosis in myelodysplastic syndromes: A prospective evaluation including mutational analysis

    Oncotarget, Vol. 7, Núm. 21, pp. 30492-30503

  2. Chromothripsis is a recurrent genomic abnormality in high-risk myelodysplastic syndromes

    PLoS ONE, Vol. 11, Núm. 10

2013

  1. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes

    Leukemia, Vol. 27, Núm. 3, pp. 610-618

  2. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine

    Annals of Hematology, Vol. 92, Núm. 11, pp. 1543-1552

2012

  1. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: Are they present at diagnosis or are they induced by lenalidomide?

    Haematologica, Vol. 97, Núm. 10, pp. 1608-1611